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Monsanto Technology LLC v. Cefetra BV" was the first European Court of Justice (ECJ)
interpretation of the twelve-year-old European Union Biotechnology Directive (Directive
98/44/EG), which established the foundation for patenting genetic material in member
countries. 2 The ECJ's decision effectively limited the scope of the directive, and conse-
quently, European biotechnology patent protection by determining that genetic patents
are only effective when the patented gene "perform[s] the function for which it is pat-
ented[.]" 3 The first part of this paper will discuss the history of the parties in dispute and
the industry that is becoming familiar to this kind of dispute. The second and third parts
will focus on the specific case that is the focus of this paper, and the final portion will
analyze the effect this case had and will continue to have on patent law, particularly in the
European Union and Argentina.
II. Background
Monsanto, the world's biggest seed company,4 provides agricultural products for farmers
in the United States and internationally.s Monsanto is a major player in global biotech-
nology innovation and business through its involvement in genetically modified seed crea-
* Craig C. Carpenter, 2012 Candidate for Juris Doctor, SMU Dedman School of Law.
1. Case C-428/08, Monsanto Tech. LLC v. Cefetra BV, 2010 E.C.R. 7, available at http://curia.curopa.eu/
jcms/jcms/j6/.
2. Richard Van Noorden, DNA Patent Ruling Hinders Monsanto, NATURE, July 9, 2010, http//
www.nature.com/news/2010/100709/full/news.2010.345.html.
3. Case C-428/08, Monsanto Tech. LLC v. Cefetra BV, 2010 E.C.R. 7.
4. Stephanie Bodoni, Monsanto May Lose Bid to Halt Argentinean Soy Imports, Bus. WEEK, Mar. 9, 2010,
http://www.businessweek.cominews/2010-03-09/monsanto-may-lose-bid-to-halt-argentinean-soy-imports-
updatel-.htnl.
5. Monsanto Co., YAHOO FIN., http://finance.yahoo.com/q/pr?s=MON (last visited Feb. 16, 2011).
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tion. The company sells genetically modified seeds to farmers worldwide and also licenses
the beneficial genes that it uses to modify the seeds to other seed producers.6 To protect
and profit from its innovation, Monsanto seeks patents on the seeds, methods of produc-
ing the seeds, and the genetic traits within the modified seeds.
In 2005 and 2006, Monsanto sued European importers of Argentine soybean meal in
Spain, the United Kingdom, Denmark, and Holland, for infringing on three of its Euro-
pean biotechnology patents.7 According to Monsanto, the imported soy meal was derived
from soy beans produced by soy plants that were modified with a gene developed by Mon-
santo.8 The patents at issue relate to a gene (known as EPSPS) that, when added into the
soy genome, confers resistance to the herbicide glyphosate, commonly known as
"Roundup."9 This trait allows farmers to use the herbicide to eliminate weeds while per-
mitting the soy plant to grow unharmed.' 0 Specifically, the patent awarded Monsanto:
[P]roprietary exclusivity over (1) isolated DNA encoding EPSPS, (2) a method of
producing a genetically transformed plant which tolerates the herbicide glyphosate by
making a transgenic plant cell containing the EPSPS gene, (3) glyphosate-tolerant
plant cells and plants, and (4) a method of controlling weeds in a field by applying
glyphosate to a crop and weeds in a field containing a crop that has been transformed
with the EPSPS gene and is therefore glyphosate-tolerant."
Monsanto alleged that the plants contained traces of the DNA from its patented gene,
which indicated that the soy meal was produced from soy plants grown from its patented
seeds.12 The suit alleged that the presence of this DNA in the soy meal violated Mon-
santo's patent rights in three ways: (1) infringement of Monsanto's patent claim of the
isolated gene, (2) infringement of Monsanto's patent claim of the method of producing
resistant plants using the gene, and (3) infringement of Monsanto's patent claim of the
DNA sequence itself.'3 Monsanto elected to enforce its patent in Europe because it did
not have patent protection in Argentina, where the patent was rejected for procedural
reasons,14 and thus Monsanto was not able to take action against Argentine farmers using
the seeds without consent.' 5
6. Id.
7. Gareth Morgan et al., Expert Analysis ofRecent European Developments Cargill vs. Monsanto, 27 BIOTECH-
NOLOGY L. REP. 109, 110 (2008).
8. Id.
9. Id. at 109.
10. Press Release, Court ofJust. of the European Union, Monsanto Cannot Prohibit the Marketing in the
EU of Soy Meal Containing, in a Residual State, a DNA Sequence Patented by It (July 6, 2010), available at
http://curia.europa.eu/jcms/upload/docs/application/pdf/2010-07/cplOO073en.pdf.
I1. Richard Peet et al., The Future of Biotecbnology Patents in the European Union, INTELL. PROP. WATCH,
Aug. 17, 2010, httpi//www.ip-watch.org/weblog/2010/08/17/the-future-of-biotechnology-patents-in-the-eu-
ropean-union/.
12. Id.
13. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
BY.) (Neth.). For an English translation, see http-J/holmancm.googlepages.com/CefetraEUBiotechDirec-
tive.pdf.
14. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
BY.).
15. Id.; see also Andrew Turley, DNA Must Do Its.Job for Patent Protection, CHEMTRY WORLD, July 8, 2010,
http-//www.rsc.org/chemiistryworld/News/2010/July/08071001.asp ("Farmers in Argentina can grow
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M. The Dutch Case
In June 2005 and March 2006, shipments of soybean meal from Argentina arrived in
harbors in the Netherlands intended for Cefetra Futures BV.16 The cargo was detained
by customs on the grounds of the Anti-Piracy Regulation (E.U. Regulation number 1383/
2003), and Monsanto took samples of the product to determine if the soy meal originated
from its patented genetically modified soybeans.' 7 Monsanto found DNA matching that
of its patented trait, and sued the importers (Cefetra and others) for patent infringement
based on its European patent (the "patent") granted June 19, 1996, under number EPO
546 090 relating to glyphosate tolerant 5-enolpyruvylshikimate-3 phosphate synthesis.'5
The European Patent Office granted the patent, which was valid in Austria, Belgium,
Switzerland, Germany, France, the United Kingdom, Italy, Lichtenstein, Luxemburg, the
Netherlands, and Sweden.19 Cefetra and the government of Argentina, a major exporta-
tion country of soy products, joined to dispute Monsanto's infringement claims.
The Dutch court, sitting in The Hague, heard the case in 2008.20 The decision con-
curred with the earlier decision by the United Kingdom High Court of Justice.21 In re-
sponse to Monsanto's claimed infringement on the isolated DNA, the Dutch court and
British court both held that "there can be no question of breach of these claims [for in-
fringement of the isolated DNA patent] as the DNA is not present as isolated matter but
is incorporated in the soy meal."22 In so finding, the court reasoned that, even though the
DNA was outside of its normal environment (the bacterial chromosome) and put into the
plant cell, "[tlhe average person skilled in the art would understand the term isolated
DNA as DNA that has been retrieved from the cell (core) of an organism for further
treatment in a manner as is usual in the relevant profession." 23 The Dutch court was
equally skeptical of Monsanto's second argument and rejected the theory "that the soy
meal can be regarded as a directly obtained product by application of the claimed meth-
ods[.]"24 The court reasoned that "[ilt can be accepted that the soy plant and soy bean
have been directly obtained by the method," but that "[b]y means of the previously de-
scribed crushing process, the beans are then separated, in a number of treatment stages,
and worked into different components with a new identity. This process is too drastic to
still assume a direct relationship between the method and the soy meal." 25 Thus, the
Roundup Ready soya beans because Monsanto does not have patent protection in the country. Monsanto
said in a recent statement that: 'Approximately 95 per cent of the soybeans grown in Argentina contain the
Roundup Ready trait.'").





20. Id.; Peet et al., supra note 11.
21. Peet et al., supra note 11.
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product (soy meal) was not "directly obtained" by the patented method (growing herbi-
cide resistant soy plants) 26 and was not protected under the patent.
Monsanto's third infringement argument prompted the most discussion by the court
and led to the present controversy. In this argument Monsanto claimed infringement of
its patent claims that relate to the DNA sequence per se, without restrictions for isolation
or method. 27 The court dismissed Cefetra's argument that the DNA present in the soy
meal was overly fragmented and in de minimus quantity to support infringement, finding
that:
[e]ven should it have to be assumed that the DNA sequence is only present in the soy
meal in minimal quantity, this does not deter from the fact that there is a breach of
the Monsanto patent, if and to the extent that the scope of protection extends to the
product, the DNA, as such[.]28
However, as the court noted, the question still remained as to whether the law even
covers the DNA at issue. An interpretation of the applicable patent standard would be
outcome determinative in this case: if the law does apply to the DNA per se, then Mon-
santo's patent was infringed upon; however, if the law does not apply to the DNA per se,
then there was no infringement. 29
The court first grappled with the applicable law; specifically, whether to apply the na-
tional (Dutch) patent law or the E.U. directive. 30 Article 9 of the E.U. Directive states:
"[t]he protection conferred by a patent on a product containing or consisting of genetic
information shall extend to all material, save as provided in Article 5(1), in which the
product is incorporated and in which the genetic information is contained and performs its
function."31 Monsanto first argued that Article 9 of the Directive should not apply because
soy meal was not a biological material. 32 Monsanto also stated that the directive was cre-
ated to expand patent protection to biotechnological inventions and not to limit it, and
therefore set a minimum standard of protection for biotechnological inventions, which
could be strengthened by the absolute protection of national law.33 Monsanto supports
26. Peet et al., supra note 11.
27. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
BY.), See also Chris Holman, Limitations on the scope of DNA Patent Claims in Europe: Monsanto Struggles in Its
Attempt to Block Importation of Soy Meal Containing Patented DNA, HotmaN's BIOTECH IP BLOG, (May 4,
2008, 9:28 EST) http-//holmansbiotechipblog.blogspot.com/2008/05/limitations-on-scope-of-dna-patent.
html (explaining "whether claims directed to the DNA sequence per se, without any limitation to 'isolated
DNA,' are infringed by the soy meal").




31. Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protec-
tion of biotechnological inventions, art. I (emphasis added), available at http-//eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX:31998L0044:EN:HTML.
32. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
B.V.).
33. Rijksoctrooiwet [Patents Act of the Kingdom] 1995, art. 53 (Neth.), available at http-//www.ivir.nl/
legislation/nl/patentactl995.htmI ("a patent shall confer on its owner the exclusive right: a. to make, use, put
on the market or resell, hire out or deliver the patented product, or otherwise deal in it in or for his business,
or to offer, import or stock it for any of those purposes"); Ktr. The Hague Maart 19, 2008, 249983/HA ZA
05/2885 m.nt (Monsanto Technology LLC/Cefetra B.V.); Holman, supra note 27.
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this argument by adding that "[sluch a limitation ... is not compatible with Article 27 of
the [Trade-Related Aspects of Intellectual Property Rights (JTRIPSDI Treaty[.]" 34 Fur-
ther, Monsanto argued that regardless of the use of Article 9 of the Directive, "the prod-
uct[] is incorporated in the soy meal and expresses its function." 35 Monsanto reasoned
that:
the requirement that the DNA expresses its function means that it is sufficient that
the DNA has exercised its function (namely the provision of resistance to glyphosate
in the soy plant) or that the DNA, should it be isolated from the soy meal, can be
incorporated in a cell in a soy plant and can then (once again) exercise its function. 36
Cefetra cited a Spanish case and an English case, which applied the purpose/function
limitation to patent protection for DNA as well as supplemental language from different
sources from the E.U.37 Noting that the decision in this case turns on the interpretation
and scope of Article 9 of the E.U. Directive (a transnational doctrine), the Dutch court
decided that such matters would be better suited to the ECJ. Thus, the Dutch court
referred the following three questions to the ECJ for clarification:
1. Should Article 9 of the Directive be understood such that the protection meant in this
Article can also be relied upon in a situation such as in these proceedings whereby the
product (the DNA) is present in a materials and does not express its function at the
time of the stated breach but has indeed expressed its function or possibly, following
the isolation from the material and its incorporation in the cell of an organism, could
once again express its function?
2. Proceeding from the presence of the DNA sequence as described in claim 6 of the
patent in soy meal imported into the European Community by Cefetra and ACTI and
assuming that DNA is incorporated in the soy meal as meant in Article 9 of the Direc-
tive and that it therein no longer expresses its function: Does the provided protection
of a patent for biological material in the Directive, specifically in Article 9, stand in
the way for the national patent legislation to (additionally) allow absolute protection
for the product (the DNA) as such, whether or not the DNA expresses its function
and must the protection provided by Article 9 therefore be considered exhaustive?
3. Does it make any difference to the answer to the previous question that the patent was
applied for and granted (on 19 June 1996) prior to the Directive being adopted? Can
you, on answering the previous questions, take into consideration the TRIPS Treaty,
specifically the Articles 27 and 30?38
34. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
B.V.); Trade-Related Aspects of Intellectual Property Rights art. 27, Apr. 15, 1994, Annex IC, 1869 U.N.T.S.
299, available at http://www.wto.org/english/docs.elegale/27-trips.pdf ("[Patents shall be available and
patent rights enjoyable without discrimination as to the place of invention, the field of technology and
whether products are imported or locally produced.").
35. Ktr. The Hague Maart 19, 2008, 249983/HA ZA 05/2885 m.nt (Monsanto Technology LLC/Cefetra
B.V.).
3 6. Id.
37. Id. ("Cefetra, Argentina and ACTI have submitted a decision by the Spanish judge ... in the case of
Monsanto-Sesostris S.A.E. . .. [they have] also submitted an opinion on the same lines by Professor Dr.
Dres. h.c. Joseph Strauss land]. . .a decision by the English High Court of Justice dated 10 October 2007 was
submitted in respect of the case Monsanto-Cargill.").
38. Id.
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IV. THE ECJ DECISION
On July 6, 2010, the ECJ made the final decision on Monsanto Tech. LLCv. Cefetra BV-
a sweeping blow against Monsanto.39 In response to the first question proposed by the
Dutch Court, the ECJ held that:
[a]rticle 9 of Directive 98/44/EC of the European Parliament . .. is to be interpreted
as not conferring patent right protection in circumstances such as those of the case in
the main proceedings, in which the patented product is contained in the soy meal,
where it does not perform the function for which it is patented, but did perform that
function previously in the soy plant, of which the meal is a processed product, or
would possibly again be able to perform that function after it had been extracted from
the soy meal and inserted into the cell of a living organism. 40
The court likewise answered the second question against Monsanto stating that
"[a]rticle 9 of the Directive effects an exhaustive harmonisation of the protection it con-
fers, with the result that it precludes the national patent legislation from offering absolute
protection to the patented product as such. . . ."41
Finally, to complete its rejection of Monsanto's arguments, the court held that:
[airticle 9 of the Directive precludes the holder of a patent issued prior to the adop-
tion of that directive from relying on the absolute protection for the patented product
accorded to it under the national legislation then applicable.... Articles 27 and 30 of
the... [TRIPS] do not affect the interpretation given of Article 9 of the Directive.42
With this decision, the Court chose sides and definitively answered a debate that has
occupied European biotechnology scholars for some time. For the purposes of the Dutch
litigation (and much to Cefetra and Argentina's delight), the court held that there could
not be infringement because the DNA was in dead material (the soy meal) and thus could
not possibly be performing its patented function (resisting herbicide).43 However, this
decision had no effect on the Dutch litigation because the parties settled outside of court
prior to the ECJ decision.4 4 Settlement or no settlement, the ECJ, possibly sensing the
urgency for clarification on its stance regarding the Directive, felt compelled to give a
decision. This urgency likely spawned from the fact that the biotechnology industry is a
controversial, $80-billion-dollar and growing industry.45 Europe has been slow to warm
up to the industry and has instead allowed the United States and Canada to take the
driver's seat with regards to biotechnology policy.46




43. Turley,supra note 15.
44. Id.
45. Glen T. Giovannetti et al., Beyond Borders Global Biotechnology Report 2010, ERNsT & YoUNG, 54
(2010), http-/www.ey.com/Publication/vwLUAssets/Beyondborders_2010/FILE/Beyondborders_2010.
pdf.
46. For a discussion on the history of biotechnology in Europe and the beginnings of the Directive, see
Terence P. Stewart & David S. Johanson, Polity in Flur: the European Union's Laws on Agricultural Biotechnology
and Their Effects on International Trade, 4 DRAKE J. Acluc. L. 243 (1999); Lydia Nenow, To Patent or Not to
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V. Effects of the Ruling
The implications for this decision are widespread, and its merits are heavily debated.
This decision, which cannot be appealed and is retroactively applicable in all twenty-seven
European Union Member States,47 essentially makes European gene patents "purpose
bound"48 in that the patent "can only be relied on [when it] actually performs the function
for which it is patented."49 Many commentators agree that this interpretation signifi-
cantly narrows the protection offered by E.U. patents;50 however, as noted below, there is
much disagreement as to how this will affect the industry as a whole.
The Court refused the argument that gene patents should be "product-based" like other
machine or chemical patents, which are granted per se protection that allows the owner to
restrict any infringing use. 5' In choosing this path, the court has carved out an exception
to patent law that treats genetic patents differently than machines and other patentable
material. 52 Opponents argue that this interpretation of the directive is troublesome and
would severely undermine patent enforcement for many biotechnology inventions.53 It is
argued that this treatment of genetic patents is counterintuitive to and inconsistent with
the way typical patent laws would approach this kind of infringement-under which, "so
long as the genetic information is present and capabk of performing its function, it should
not matter whether the genetic information is active at the time of the alleged infringing
act, unless some other claim element requires it[ ]."54 This argument has teeth when ap-
plied to this case. Monsanto's patented material was found in the imported soy meal, and
it can be said that the soy meal could not have existed were it not for Monsanto's patented
material-under traditional patent law this could be a fairly straightforward infringement.
In this vein, problems also arise because "[mlany genes are only expressed for a limited
time period or in specific tissues in a living organism."55
Some commentators claim that this ruling allows for a lucrative loophole for patent
infringement because growers could potentially "circumvent gene patents used to protect
genetically modified crops by growing the crops in a country where the gene is not pat-
ented, such as Argentina in this case,. . . and then importing the product into a European
Union member wherein the patent is in force with impunity."56 This is an important
global argument. From a business standpoint, biotech companies rely on the limited mo-
Patent: The European Union's New Biotech Directive, 23 Hous.J. INT'L L. 569 (2001); Samantha A. Jameson, A
Comparison of the Patentability and Patent Scope of Biotechnological Inventions in the United States and the European
Union, 35 AIPLA Qj. 193 (2007).
47. Jeremy Phillips, Monsanto: Court Makes a Meal of Soya Ruling, IPKAT BLoc, (uly 6, 2010), httpl/
ipkitten.blogspot.com/2010/07/monsanto-court-makes-meal-of-soya.htnl.
48. Morgan et al., supra note 7, at 112.
49. Agriculture: EU Court Rejects Monsanto Demand for EU Ban on Argentine Soya Imports, 27 INT'L TRADE
REP. (BNA) No. 1034 (July 8, 2010).
50. Van Noorden, supra note 2.
51. Morgan et al., supra note 7, at 112.
52. Turleysupra note 15.
53. Peet et al., supra note 11.
54. Id. (emphasis added).
55. Id.
56. Chris Holman, Monsanto v. Cefetra: EU Court ofJustice Limits Scope of Patent Protection Available to Gene
Sequences, HolMAN's BIOTECH IP BLOG, (July 9, 2010, 16:37 EST), http-//holmansbiotechipblog.blogspot.
comf/ 2 0 10/07/monsanto-v-cefetra-eu-court-of-justice.html.
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nopolies granted by patents to offset the huge research and development costs commonly
found in scientific fields. Additionally, as developing countries like Argentina5 7 continue
to grow their agricultural export markets, 58 genetically-modified-organism patent protec-
tion will be of great concern to international companies. The potential loophole created
by the ruling in this case could have an expensive impact on companies like Monsanto and
undermine the efforts for global intellectual harmonization. 59 Because of this ruling, fu-
ture action to reconcile this kind of "infringement" will have to focus on the court systems
in the agricultural countries like Argentina, instead of patent protection in export destina-
tions.60 Many commentators stress that, so far, Argentine intellectual property protection
has come up short of expectations from the rest of the intellectual property world. 61
However, there is also strong support for the court's decision. Many countries in Eu-
rope have expressly or implicitly showed skepticism toward product-based patent protec-
tion for genetic information,62 including the United Kingdom, which has held that "while
it may be true to say ... that [the DNA] lay 'at the heart of the invention', it was not the
invention. An invention is a practical product or process, not information about the natu-
ral world." 63 In that sense, this ruling harmonizes the E.U.'s stance on gene patents with
that of some of the individual European countries.64 Proponents (the Argentina govern-
ment included) find the limits imposed by this ruling necessary to prevent overly broad
protection, even concluding that "[i]f the court decided that Monsanto can invoke its
rights in the EU against soy meal originating from Argentina, nothing could stop it to
then use its rights against soy meal coming from other countries[.]" 65 Others do not see
this situation becoming as much of a catastrophe, arguing that:
[a]lthough lawyers will have to be careful about how they file patents for products
containing genetic material, most . .. feel that the ruling will probably not dampen
innovation or investment in the European biotech industry as a whole. If anything
57. Argentina is one of the world's top exporters of soy-bean products. Balance of Trade: Argentine Exports
Up 15 Percent to Record $46.57 Billion in 2006, 24 Ir'L TRADE REP. (BNA) No. 176 (Feb. 1, 2007) ("Among
[Argentine] exports, $8.86 billion came from soybean and soy byproducts, according to Indec. Argentina is
the world's top exporter of soybean oil and the third largest exporter of soy beans.").
58. See id.
59. 41st World Intellectual Property Congress A Resounding Success, Bus. WIRE, Sept. 26, 2008, available at
http//findarticles.com/p/articles/mi-m0EIN/is_2008_Sept-26/ai-n29462689/.
60. EU Court Ruling Favours Argentina in Dispute With Monsanto Over Soy-Seed Patent, MERCOPRESs, July 8,
2010, httpI//en.mercopress.com/2010/07/08/eu-court-ruling-favours-argentina-in-dispute-with-monsanto-
over-soy-seed-patent (noting that, in anticipation of this ruling, the dispute between the two major players in
the litigation, Monsanto and Cefetra, was settled outside of court and Monsanto is pursuing its options in
Argentina, stating that Argentina was "the correct place for a resolution in these matters" and that "it will
continue to work on a fair solution").
61. Protection of Biotechnological Inventions in Argentina, APLF PATErr L. UPDATE, May 15, 2007, httpi/
www.aplf.org/protection-of-biotechnological-inventions-in-argentinal.
62. Morgan et al., supra note 7, at 112 ("It is worth noting that in implementing the Biotechnology Direc-
tive, Germany, France, and Luxembourg have all expressly barred gene sequences from product-based
protection.").
63. Kirin-Amgen Inc. v. Hoechst Marion Roussel Ltd, [2004 UKHL 46 (appeal taken from EWCA)
(Eng.).
64. Morgan et al., supra note 7, at 112.
65. Bodoni, supra note 4.
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... the court decision shows that DNA patents are acceptable in Europe, even if their
scope is quite narrow.66
Some of these commentators put more faith in the patent-seeking companies and ex-
port countries, rationalizing Monsanto's current dilemma as an unfortunate mistake be-
cause "Monsanto's lack of patent protection in Argentina is anomalous. In most cases, if
your claim is in Argentina, you'd be able to stop them in Argentina.... Biotechnology
companies with 'good coverage' are unlikely to be worried." 67 Additionally, all hope for
the protection sought by Monsanto is not lost-patents can be prepared (by a prudent
author) with other claims that could be used to enforce protection on products containing
genetic material without relying on a claim for the DNA sequence, which was ineffective
for Monsanto in this case.68 Inventors seeking patent protection for genetic information
and the products created by such innovation will need to be aware of the "purpose-bound"
distinction and creatively work around it in the patent claims to create optimal protection
for their products.
VI. Conclusion
The ECJ's analysis of the twelve-year-old European Union Biotechnology Directive in
the ruling in Monsanto Technology LLC v. Cefetra BV marks an important and definitive
interpretation of European patent law. The finding that European Union patent protec-
tion of genetic material is "purpose-bound" helps clarify a murky area of patent law but
places a significant limitation on biotechnology patents in Europe and may cause many
holders of such patents to reconsider their comfort level with their patent portfolio. This
insecurity reigns over the biotech industry as a whole; even countries that have shown
early support for the biotech industry (like the United States) are struggling with applica-
tion of patent law to this cutting-edge industry.69 While the total effect of this interpreta-
tion of biotechnology patent law on the related industries remains to be seen, it is clear
that, for Monsanto and other genetically modified organism innovators, the battlefield
will shift from major import countries like those in Europe to the agricultural export
countries, such as Argentina (where they may be met with courts immature in patent
experience). As the biotechnology industry continues to expand, both in scope and con-
troversy, legislation will have to hustle to keep up with the science.
66. Van Noorden, supra note 2.
67. Turley, supra note 15 (internal quotation marks omitted).
68. Van Noorden, supra note 2.
69. See e.g., Andrew Pollack, U.S. Says Genes Should Not Be Eligible for Patents, N.Y. TUWEs, Oct. 30, 2010, at
B1 (noting that recent litigation has the United States possibly on the cusp of revising its longstanding policy
towards patents for isolated genes), available at http-//www.nytimes.com/2010/10/30/business/30drug.html?-
r=1 &scp=2&sq=andrew%20pollack&st=cse.
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